Long-Term Care Facilities and Virus - Drug Discovery Digest

ECDC and EMA highlight considerations for additional and booster doses.

The Pharma Data

SEPTEMBER 6, 2021

To complement vaccination efforts, it is also crucial to continue applying measures such as physical distancing, hand and respiratory hygiene, and using face masks where needed, in particular in high-risk settings such as long-term care facilities or hospital wards with patients at risk of severe COVID-19.

Long-Term Care Facilities

Long-Term Care Facilities Vaccine Immune Response Virus

Walgreens Statement Regarding FDA Emergency Use Authorization of COVID-19 Vaccine

The Pharma Data

DECEMBER 11, 2020

We will be collaborating with nearly 35,000 skilled nursing and assisted living facilities nationwide that have selected Walgreens as their vaccine provider. Our purpose – to champion the health and wellbeing of every community in America – has never been more clear or critical,” said John Standley, Walgreens president.

Long-Term Care Facilities

Long-Term Care Facilities Vaccine Pharmacy Assisted Living

Analysis Chemical Thank You EPA issues guidance for disinfectant product claims used on soft surface textiles in non-residential settings

Agency IQ

SEPTEMBER 6, 2023

Commenters also provided edits to both the virus and bacterial methods, as well as the claim and use sites. Stakeholders were also concerned about the interpretation and clarity of the term “porous surface.” One was for use against viruses and one was for combating bacteria. Other concerns focused on guidance and label language.

Production

Production Virus Long-Term Care Facilities Laboratories

Keeping tabs on Covid-19: BioNTech buys GMP-certified facility to boost vaccine…

The Pharma Data

SEPTEMBER 18, 2020

Olivia Karpinski, vice-president of sales at Vivera Pharmaceuticals, said: “We have worked closely with our customers, including long-term care facilities and hospital networks, to provide efficient solutions for their increased testing needs.”

Vaccine

Vaccine Long-Term Care Facilities Clinical Supply Laboratories

Therma Bright Acquires 100% Control of its COVID-19 Rapid Saliva Antigen Test and Announces Proposed Name Change for the Test

The Pharma Data

JANUARY 24, 2021

” Therma Bright is not making any express or implied claims that its product, SCV2, has the ability to eliminate or cure COVID-19 (or SARS-CoV-2 virus). The test can help identify infected individuals in 15 minutes and is designed for at-home or point-of-need settings such as long-term care facilities, schools, or sporting events.

Long-Term Care Facilities

Long-Term Care Facilities Virus FDA Regulations

bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.

The Pharma Data

APRIL 16, 2021

1.429 California strain that currently accounts for 50 percent of the virus in California and over 10 percent across a number of additional states. However, sites of care should not dispose of bamlanivimab supply; instead, they should order etesevimab to pair with it. All sites in the U.S. In the U.S.,

Treatment

Treatment Hospitals Long-Term Care Facilities Virus

FDA Advisory Panel Says Yes to Pfizer’s COVID Vaccine

The Pharma Data

DECEMBER 10, 2020

First in line are health care personnel and residents and staff of long-term care facilities, according to earlier recommendations released by the CDC panel. Centers for Disease Control and Prevention will also vote on whether to recommend the vaccine and for whom, the Post reported. and Troy, Mich. —

Vaccine

Vaccine FDA Long-Term Care Facilities Hospitals

Biden Will Ask Americans to Wear Masks for 100 Days

The Pharma Data

DECEMBER 4, 2020

And I think we’ll see a significant reduction” in the virus, Biden told CNN. The recommendation from the Advisory Committee on Immunization Practice (ACIP), if heeded, will steer the initial short supply of vaccines to about 21 million health care personnel and 3 million Americans working or living in long-term care facilities.

Long-Term Care Facilities

Long-Term Care Facilities Vaccine Nurses Hospitals

CDC Director Warns of Dire Winter Ahead for COVID Hospitalizations, Deaths

The Pharma Data

DECEMBER 3, 2020

Though coronavirus cases have exploded recently, with new infections topping 1 million a week, a far smaller proportion of people who get the virus now are dying from it. Things are not shut down.” ” One positive? CDC data shows that the share of cases resulting in death dropped from 6.7 percent in April to 1.9

Hospitals

Hospitals Long-Term Care Facilities Vaccine Nurses

Bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together

The Pharma Data

APRIL 14, 2021

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing.

Government

Government Long-Term Care Facilities Hospitals Treatment

Britain Approves Emergency Use of Pfizer’s COVID Vaccine

The Pharma Data

DECEMBER 2, 2020

The recommendation from the Advisory Committee on Immunization Practice (ACIP), if heeded, will steer the initial short supply of vaccines to about 21 million health care personnel and 3 million Americans working or living in long-term care facilities. Hospitalizations reach record high.

Vaccine

Vaccine Long-Term Care Facilities Hospitals Nurses

U.S. CDC Advisory Committee on Immunization Practices Recommends Vaccination with Moderna’s COVID-19 Vaccine for Persons 18 Years and Older

The Pharma Data

DECEMBER 19, 2020

Today’s ACIP recommendation follows the December 1, 2020 ACIP recommendation for a Phase 1a rollout in which the first priority for COVID-19 vaccines is given to healthcare personnel treating patients and residents in long-term care facilities. Department of Health and Human Services (HHS) for review and adoption.

Vaccine

Vaccine Long-Term Care Facilities FDA Licensing

Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries | Eli Lilly and Company

The Pharma Data

MAY 4, 2021

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing.

Therapies

Therapies Hospitals FDA Approval Long-Term Care Facilities

Drop in COVID Cases Seen in Nursing Homes as U.S. Vaccine Effort Makes Headway

The Pharma Data

FEBRUARY 1, 2021

million shots have now been administered in long-term care facilities, according to the U.S. 1.351 variant contains a key mutation that appears to allow the virus to elude the full power of antibody treatments and vaccines. “I’m optimistic, this is good.” ” As of Saturday, more than 3.5

Nurses

Nurses Vaccine Long-Term Care Facilities Virus

Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19

The Pharma Data

JUNE 25, 2021

AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus.

Trials

Trials Long-Term Care Facilities Virus Government

Study Suggests Link Between Sleep Supplement and COVID-19

The Pharma Data

DECEMBER 21, 2020

Each of the vaccines targets the “spike protein” found on the surface of the virus that causes the illness. This typically allows the virus to attach itself to host cells and infect them. However, there are two vaccines that have been authorized in the U.S. for emergency use: one from Moderna, and one from Pfizer and BioNTech.

Long-Term Care Facilities

Long-Term Care Facilities Vaccine Virus Clinical Trials

Clinical Catch-Up: January 18-22 | BioSpace

The Pharma Data

JANUARY 24, 2021

National Institute of Allergy and Infectious Diseases (NIAID), of bamlanivimab (LY-CoV555) decreased the risk of COVID-19 among residents and staff of long-term care facilities, i.e., nursing homes. It is a virus-based therapeutic vaccine that encodes neoantigens picked by NEC’s Neoantigen Prediction System.

Long-Term Care Facilities

Long-Term Care Facilities Trials Virus Clinical Trials

Lilly Announces Agreement with U.S. government to Supply 300,000 vials of Investigational Neutralizing Antibody Bamlanivimab (LY-CoV555) in an Effort to Fight COVID-19

The Pharma Data

OCTOBER 28, 2020

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially preventing and treating COVID-19. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing.

Government

Government Long-Term Care Facilities Hospitals Therapies

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

The Pharma Data

JANUARY 26, 2021

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing.

Hospitals

Hospitals Treatment Long-Term Care Facilities Trials

Lilly’s Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for the Treatment of Recently Diagnosed COVID-19

The Pharma Data

NOVEMBER 9, 2020

. “The BLAZE-1 data show bamlanivimab, when given early in the disease course, may help patients clear the virus and reduce COVID-related hospitalizations, supporting our belief that neutralizing antibodies can be an important therapeutic option for patients fighting this virus,” said Daniel Skovronsky, M.D.,

Treatment

Treatment FDA Hospitals Long-Term Care Facilities

Health Highlights: Dec. 14, 2020

The Pharma Data

DECEMBER 14, 2020

” Initial public COVID-19 vaccination is focused on front-line health workers and people in nursing homes and long-term care facilities, the AP reported. What a horrible, horrible virus. I am not scheduled to take the vaccine, but look forward to doing so at the appropriate time.” © 2020 HealthDay.

Long-Term Care Facilities

Long-Term Care Facilities Vaccine Nurses Virus

Biden Says He Will Release All Vaccine Doses After Taking Office

The Pharma Data

JANUARY 8, 2021

We are in a race with this virus, so anything that speeds vaccination should be applauded.” There are about 21 million health care workers and about 3 million people at long-term care facilities, so their inoculations will account for the first 48 million doses of the two-dose vaccine.

Vaccine

Vaccine Long-Term Care Facilities Hospitals FDA

EMA issues advice on Lilly’s bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union

The Pharma Data

MARCH 5, 2021

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing.

Treatment

Treatment Hospitals Long-Term Care Facilities Therapies

Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19

The Pharma Data

MARCH 11, 2021

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing.

Hospitals

Hospitals Trials Long-Term Care Facilities Treatment

‘Warp Speed’ Officials Say U.S. COVID Vaccine Distribution Too Slow

The Pharma Data

DECEMBER 31, 2020

According to the Times , he said that health care facilities are still learning how to store the vaccines at super-low temperatures, and many states are setting aside doses for use at long-term care facilities, an effort that’s expected to take several months.

Vaccine

Vaccine Long-Term Care Facilities Virus Hospitals

Drug Discovery Digest

ECDC and EMA highlight considerations for additional and booster doses.

Walgreens Statement Regarding FDA Emergency Use Authorization of COVID-19 Vaccine

Trending Sources

Analysis Chemical Thank You EPA issues guidance for disinfectant product claims used on soft surface textiles in non-residential settings

Keeping tabs on Covid-19: BioNTech buys GMP-certified facility to boost vaccine…

Therma Bright Acquires 100% Control of its COVID-19 Rapid Saliva Antigen Test and Announces Proposed Name Change for the Test

bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.

FDA Advisory Panel Says Yes to Pfizer’s COVID Vaccine

Biden Will Ask Americans to Wear Masks for 100 Days

CDC Director Warns of Dire Winter Ahead for COVID Hospitalizations, Deaths

Bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together

Britain Approves Emergency Use of Pfizer’s COVID Vaccine

U.S. CDC Advisory Committee on Immunization Practices Recommends Vaccination with Moderna’s COVID-19 Vaccine for Persons 18 Years and Older

Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries | Eli Lilly and Company

Drop in COVID Cases Seen in Nursing Homes as U.S. Vaccine Effort Makes Headway

Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19

Study Suggests Link Between Sleep Supplement and COVID-19

Clinical Catch-Up: January 18-22 | BioSpace

Lilly Announces Agreement with U.S. government to Supply 300,000 vials of Investigational Neutralizing Antibody Bamlanivimab (LY-CoV555) in an Effort to Fight COVID-19

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

Lilly’s Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for the Treatment of Recently Diagnosed COVID-19

Health Highlights: Dec. 14, 2020

Biden Says He Will Release All Vaccine Doses After Taking Office

EMA issues advice on Lilly’s bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union

Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19

‘Warp Speed’ Officials Say U.S. COVID Vaccine Distribution Too Slow

Stay Connected